New combo therapy aims to shrink rectal tumors before surgery

NCT ID NCT07284992

Recruiting now Disease control Sponsor: Shandong Provincial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial compares two types of radiotherapy (short-course vs long-course) given alongside immunotherapy (Adebrelimab) and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see which approach leads to a higher rate of complete tumor disappearance. About 208 participants will be randomly assigned to one of the two treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (PD-L1 inhibitor) plus capecitabine and oxaliplatin chemotherapy
What this could lead to: If successful, this could lead to a more effective pre-surgery treatment for locally advanced rectal cancer, potentially increasing the chance of complete tumor disappearance before surgery.
What could go wrong: This is an early phase 2 trial with only 208 participants, so results may not apply to all patients. The combination of treatments may cause significant side effects, and it is not yet known if it improves long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED STAGE COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED STAGE COLORECTAL CANCER RADIOTHERAPY RECTAL CANCER

Contacts and locations

Locations

Shandong Provincial Hospital Affiliated to Shandong First Medical University
RECRUITING

Jinan, Shandong, 250021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.